Cargando…
Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various fact...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133463/ https://www.ncbi.nlm.nih.gov/pubmed/37122856 http://dx.doi.org/10.3389/fbioe.2023.1158484 |
_version_ | 1785031570391826432 |
---|---|
author | Mahmoudvand, Golnaz Karimi Rouzbahani, Arian Razavi, Zahra Sadat Mahjoor, Mohamad Afkhami, Hamed |
author_facet | Mahmoudvand, Golnaz Karimi Rouzbahani, Arian Razavi, Zahra Sadat Mahjoor, Mohamad Afkhami, Hamed |
author_sort | Mahmoudvand, Golnaz |
collection | PubMed |
description | Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various factors such as endothelial dysfunction and synthesis of advanced glycation end-products, hence, conventional therapeutic interventions might not be effective. With increasing therapeutic applications of mesenchymal stem cells (MSCs) in recent years, their potential as a method for improving the wound-healing process has gained remarkable attention. In this field, mesenchymal stem cells exert their beneficial effects through immunomodulation, differentiation into the essential cells at the site of ulcers, and promoting angiogenesis, among others. In this article, we review cellular and molecular pathways through which mesenchymal stem cell therapy reinforces the healing process in non-healing Diabetic foot ulcers. |
format | Online Article Text |
id | pubmed-10133463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101334632023-04-28 Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight Mahmoudvand, Golnaz Karimi Rouzbahani, Arian Razavi, Zahra Sadat Mahjoor, Mohamad Afkhami, Hamed Front Bioeng Biotechnol Bioengineering and Biotechnology Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various factors such as endothelial dysfunction and synthesis of advanced glycation end-products, hence, conventional therapeutic interventions might not be effective. With increasing therapeutic applications of mesenchymal stem cells (MSCs) in recent years, their potential as a method for improving the wound-healing process has gained remarkable attention. In this field, mesenchymal stem cells exert their beneficial effects through immunomodulation, differentiation into the essential cells at the site of ulcers, and promoting angiogenesis, among others. In this article, we review cellular and molecular pathways through which mesenchymal stem cell therapy reinforces the healing process in non-healing Diabetic foot ulcers. Frontiers Media S.A. 2023-04-13 /pmc/articles/PMC10133463/ /pubmed/37122856 http://dx.doi.org/10.3389/fbioe.2023.1158484 Text en Copyright © 2023 Mahmoudvand, Karimi Rouzbahani, Razavi, Mahjoor and Afkhami. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Mahmoudvand, Golnaz Karimi Rouzbahani, Arian Razavi, Zahra Sadat Mahjoor, Mohamad Afkhami, Hamed Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title | Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title_full | Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title_fullStr | Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title_full_unstemmed | Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title_short | Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight |
title_sort | mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: new insight |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133463/ https://www.ncbi.nlm.nih.gov/pubmed/37122856 http://dx.doi.org/10.3389/fbioe.2023.1158484 |
work_keys_str_mv | AT mahmoudvandgolnaz mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight AT karimirouzbahaniarian mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight AT razavizahrasadat mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight AT mahjoormohamad mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight AT afkhamihamed mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight |